MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX™ inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Life Sciences

Pharmaceutical

Therapeutics

MAP Pharmaceuticals

Nelson

Map Pharmaceuticals Alumni

Paul Boyd

Dallas Fairbanks

Clinical and Research Operations

Leadership Team

Teams at MAP Pharmaceuticals

Clinical and Research Operations

Leadership Team